Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result ...

Results from the phase 3 EPCORE DLBCL-1 clinical trial show that patients with relapsed or refractory diffuse large B-cell ...

Topline results show that epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an improvement in PFS in patients receiving epcoritamab monotherapy (HR, 0.74; 95 ...

Danish biotechnology company Genmab has announced top line results from the Phase III EPCORE DLBCL-1 trial, highlighting ...

North Chicago, Illinois Monday, January 19, 2026, 15:00 Hrs [IST] ...

Novartis has announced that the FDA has granted a breakthrough therapy designation to ianalumab, a treatment for Sjögren’s ...

Murphy Oil Corporation today announced results from the Civette exploration well in Block CI-502 offshore Côte d'Ivoire. The Civette-1X well reached a total depth of 13,950 feet (4,252 meters) and ...

FDA grants Breakthrough Therapy status to NVS's ianalumab for Sjogren's disease with plans for global filings starting in 2026.

Investing.com -- Genmab (CSE:GMAB) stock tumbled 5.9% on Monday after the company’s Phase 3 EPCORE DLBCL-1 trial for epcoritamab failed to meet a key secondary endpoint in patients with relapsed or ...

TB remains the leading cause of death among people living with HIV. Uganda is a high TB-burden country, and HIV accelerates ...

Novartis has announced that ianalumab has received Breakthrough Therapy designation from the US FDA to treat Sjögren’s disease.

US FDA grants Breakthrough Therapy designation to Novartis’ ianalumab for Sjögren’s disease: Basel Monday, January 19, 2026, 12:00 Hrs [IST] Novartis announced that the US Fo ...